Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-03-30 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
M | Common Stock | A | 50404 | $0.00 - $0.00 | $0 |
| 2024-03-30 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
F | Common Stock | D | 25546 | $20.67 - $20.67 | $528,035 |
| 2024-02-20 | EyePoint Pharmaceuticals, Inc. | Duker Jay S.
(President and CEO) |
G | Common Stock | D | 40000 | $0.00 - $0.00 | $0 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
M | Common Stock | A | 37534 | $0.00 - $0.00 | $0 |
| 2024-02-13 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
G | Common Stock | D | 149362 | $0.00 - $0.00 | $0 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
F | Common Stock | D | 14943 | $28.80 - $28.80 | $430,357 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
M | Common Stock | A | 10800 | $0.00 - $0.00 | $0 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
F | Common Stock | D | 5083 | $28.80 - $28.80 | $146,390 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
M | Common Stock | A | 9967 | $0.00 - $0.00 | $0 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
F | Common Stock | D | 3656 | $28.80 - $28.80 | $105,292 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Elston George
(Chief Financial Officer) |
M | Common Stock | A | 10800 | $0.00 - $0.00 | $0 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Elston George
(Chief Financial Officer) |
F | Common Stock | D | 3192 | $28.80 - $28.80 | $91,929 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Duker Jay S.
(President and CEO) |
M | Common Stock | A | 11967 | $0.00 - $0.00 | $0 |
| 2024-02-09 | EyePoint Pharmaceuticals, Inc. | Duker Jay S.
(President and CEO) |
F | Common Stock | D | 3533 | $28.80 - $28.80 | $101,750 |
| 2024-02-02 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
S | Common Stock | D | 209 | $28.49 - $28.49 | $5,954 |
| 2024-02-02 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
M | Common Stock | A | 209 | $11.47 - $11.47 | $2,397 |
| 2024-01-26 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
S | Common Stock | D | 26017 | $25.27 - $25.45 | $660,370 |
| 2024-01-26 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
M | Common Stock | A | 26017 | $3.26 - $12.90 | $177,397 |
| 2024-01-25 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
S | Common Stock | D | 600 | $25.00 - $25.00 | $15,000 |
| 2024-01-25 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
M | Common Stock | A | 600 | $12.90 - $13.13 | $7,809 |
| 2024-01-24 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
S | Common Stock | D | 11900 | $25.00 - $25.01 | $297,620 |
| 2024-01-24 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
M | Common Stock | A | 11900 | $3.26 - $12.90 | $95,669 |
| 2024-01-23 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
S | Common Stock | D | 16386 | $25.00 - $25.02 | $409,790 |
| 2024-01-23 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
M | Common Stock | A | 16386 | $12.90 - $13.13 | $213,378 |
| 2024-01-23 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
S | Common Stock | D | 35000 | $24.97 - $24.98 | $874,198 |
| 2024-01-22 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
S | Common Stock | D | 35066 | $22.24 - $25.00 | $795,191 |
| 2024-01-22 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
M | Common Stock | A | 35066 | $3.26 - $12.90 | $360,148 |
| 2024-01-11 | EyePoint Pharmaceuticals, Inc. | Ocumension Therap...
(Director) |
S | common stock | D | 1910500 | $19.45 - $19.45 | $37,159,225 |
| 2024-01-11 | EyePoint Pharmaceuticals, Inc. | Liu Ye
(Director) |
S | Common Stock, $0.001 par value | D | 1910500 | $19.45 - $19.45 | $37,159,225 |
| 2024-01-08 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
S | Common Stock | D | 22913 | $21.13 - $21.13 | $484,124 |
| 2024-01-08 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
M | Common Stock | A | 22913 | $3.26 - $3.26 | $74,696 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
M | Common Stock | A | 15285 | $0.00 - $0.00 | $0 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Paggiarino Dario A.
(Chief Medical Officer) |
F | Common Stock | D | 4487 | $20.40 - $20.40 | $91,534 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
M | Common Stock | A | 75133 | $0.00 - $0.00 | $0 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
F | Common Stock | D | 23043 | $20.40 - $20.40 | $470,077 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Pine Michael Craig
(Chief Corp Dev.&Strat. Officer) |
M | Common Stock | A | 15285 | $0.00 - $0.00 | $0 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Pine Michael Craig
(Chief Corp Dev.&Strat. Officer) |
F | Common Stock | D | 5966 | $20.40 - $20.40 | $121,706 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
M | Common Stock | A | 15285 | $0.00 - $0.00 | $0 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Jones David Scott
(SVP & Chief Commercial Officer) |
F | Common Stock | D | 4147 | $20.40 - $20.40 | $84,598 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Duker Jay S.
(President and CEO) |
M | Common Stock | A | 20793 | $0.00 - $0.00 | $0 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Duker Jay S.
(President and CEO) |
F | Common Stock | D | 6528 | $20.40 - $20.40 | $133,171 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Elston George
(Chief Financial Officer) |
M | Common Stock | A | 15285 | $0.00 - $0.00 | $0 |
| 2024-01-06 | EyePoint Pharmaceuticals, Inc. | Elston George
(Chief Financial Officer) |
F | Common Stock | D | 4911 | $20.40 - $20.40 | $100,184 |
| 2023-12-28 | EyePoint Pharmaceuticals, Inc. | Lurker Nancy
(Executive Vice Chair) |
G | Common Stock | D | 104416 | $0.00 - $0.00 | $0 |
| 2023-12-08 | EyePoint Pharmaceuticals, Inc. | Cormorant Global ...
(AtLeastTenPercentOwner) |
P | Common Stock | A | 588235 | $17.00 - $17.00 | $9,999,995 |
| 2023-12-05 | EyePoint Pharmaceuticals, Inc. | Liu Ye
(Director) |
S | Common Stock, $0.001 par value | D | 1000000 | $18.41 - $19.91 | $19,510,636 |
| 2023-12-04 | EyePoint Pharmaceuticals, Inc. | Pine Michael Craig
(Chief Corp Dev.&Strat. Officer) |
S | Common Stock | D | 45000 | $22.00 - $22.00 | $990,000 |
| 2023-12-04 | EyePoint Pharmaceuticals, Inc. | Cormorant Global ...
(AtLeastTenPercentOwner) |
P | Common Stock | A | 1919057 | $18.80 - $34.49 | $41,874,142 |
| 2023-12-04 | EyePoint Pharmaceuticals, Inc. | Pine Michael Craig
(Chief Corp Dev.&Strat. Officer) |
M | Common Stock | A | 45000 | $12.62 - $12.62 | $567,900 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |